Easier version to read at my documents with edited version
Many patients on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors achieve extremely low low-density lipoprotein cholesterol (LDL-C) levels.
Extremely low LDL-C levels are associated with even less cardiovascular risk.
Extremely low LDL-C concentrations cause no clinically relevant side effects.Low LDL-C levels due to higher clearance are a marker of adequate LDL–LDLreceptor function.
In conclusion, the clinical and physiological evidence makes the case that extremely low LDL-C plasma concentrations mediated by increased LDLR activity are not associated with significant adverse effects, within the limitations of the available clinical trial data.
Given that the main function of LDL metabolism is cholesterol excretion, therapies that increase LDLR activity could provide optimization of this physiological role.
In other words, extremely low LDL-C concentrations due to increased receptor-mediated clearance should be interpreted as a marker of adequate LDL-LDLR pathway function.